Evidence map›Paper›PMID 41760952›Full record

Trial reportNature medicine2026

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, John J P Kastelein, Christie M Ballantyne, Kausik K Ray, Ann Marie Navar, Steven E Nissen, Anne C Goldberg, Liam R Brunham and 13 more

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Novel Lipoprotein (a) Therapies: A Comprehensive Review.Current atherosclerosis reports · 2026
    Review
  4. Article
  5. Review
  6. Familial Hypercholesterolemia.Methodist DeBakey cardiovascular journal · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Stephen J NichollsVictorian Heart Institute, Monash University, Clayton, Victoria, Australia. stephen.nicholls@monash.edu.ORCID http://orcid.org/0000-0002-9668-4368
Adam J NelsonVictorian Heart Institute, Monash University, Clayton, Victoria, Australia.ORCID http://orcid.org/0000-0003-0990-2548
Marc DitmarschNewAmsterdam Pharma, Amsterdam, the Netherlands.
John J P KasteleinNewAmsterdam Pharma, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-2018-4532
Christie M BallantyneBaylor College of Medicine, Houston, TX, USA.
Kausik K RayImperial College London, London, UK.
Ann Marie NavarUT Southwestern, Dallas, TX, USA.
Steven E NissenCleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-7231-6464
Anne C GoldbergWashington University School of Medicine, St Louis, MO, USA.
Liam R BrunhamDepartment of Medicine and Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-3686-3807
Erin WuerdemanNewAmsterdam Pharma, Amsterdam, the Netherlands.
Annie L NeildNewAmsterdam Pharma, Amsterdam, the Netherlands.
Douglas KlingNewAmsterdam Pharma, Amsterdam, the Netherlands.
Andrew HsiehNewAmsterdam Pharma, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-6671-6878
Julie ButtersVictorian Heart Institute, Monash University, Clayton, Victoria, Australia.ORCID http://orcid.org/0009-0008-8755-8803
Brian A FerenceCentre for Naturally Randomized Trials, University of Cambridge, Cambridge, UK.
Ulrich LaufsKlinik und Poliklinik für Kardiologie, Leipzig University, Leipzig, Germany.
Maciej BanachMedical University of Lodz, Lodz, Poland.ORCID http://orcid.org/0000-0001-6690-6874
Roxana MehranMt Sinai School of Medicine, New York, NY, USA.
Alberico L CatapanoUniversity of Milan and Multimedica IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-7593-2094
Michael SzarekUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Violeta BalinskaiteMedpace, Cincinnati, OH, USA.
Michael H DavidsonNewAmsterdam Pharma, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most patients with heterozygous familial hypercholesterolemia fail to achieve adequate low-density lipoprotein (LDL) cholesterol lowering. Here we carried out a randomized trial to test the safety and efficacy of obicetrapib, a highly selective cholesteryl ester transfer protein inhibitor that lowers LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia and an LDL cholesterol level ≥70 mg dl

Indexed as

Anticholesteremic AgentsCholesterol Ester Transfer ProteinsHyperlipoproteinemia Type IIAdultAgedApolipoproteins BCholesterol, LDLFemaleHeterozygoteHumansMaleMiddle AgedTreatment OutcomeAnticholesteremic AgentsApolipoproteins BCholesterol Ester Transfer ProteinsCholesterol, LDL

Identifiers

PMID41760952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.